The US Bankruptcy Court gave an order approving the sale of substantially all the assets of Eiger BioPharmaceuticals, Inc. on April 24, 2024. The debtor has been authorized to sell of substantially all its assets to Sentynl Therapeutics, Inc., for a purchase price of $45.20 million. The debtor did not receive any other competing bids for the purchase of its assets and therefore Sentynl Therapeutics, Inc emerged as the winning bidder.